{"pmid":32296069,"title":"Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study.","text":["Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study.","Signal Transduct Target Ther","Tan, Li","Wang, Qi","Zhang, Duanyang","Ding, Jinya","Huang, Qianchuan","Tang, Yi-Quan","Wang, Qiongshu","Miao, Hongming","32296069"],"journal":"Signal Transduct Target Ther","authors":["Tan, Li","Wang, Qi","Zhang, Duanyang","Ding, Jinya","Huang, Qianchuan","Tang, Yi-Quan","Wang, Qiongshu","Miao, Hongming"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32296069","week":"202016|Apr 13 - Apr 19","doi":"10.1038/s41392-020-0148-4","source":"PubMed","topics":["Treatment","Mechanism","Diagnosis"],"weight":1,"_version_":1664266651247312897,"score":8.233237,"similar":[{"pmid":32226636,"pmcid":"PMC7100419","title":"Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study.","text":["Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study.","Signal Transduct Target Ther","Tan, Li","Wang, Qi","Zhang, Duanyang","Ding, Jinya","Huang, Qianchuan","Tang, Yi-Quan","Wang, Qiongshu","Miao, Hongming","32226636"],"journal":"Signal Transduct Target Ther","authors":["Tan, Li","Wang, Qi","Zhang, Duanyang","Ding, Jinya","Huang, Qianchuan","Tang, Yi-Quan","Wang, Qiongshu","Miao, Hongming"],"date":"2020-04-01T11:00:00Z","year":2020,"_id":"32226636","week":"202014|Mar 30 - Apr 05","doi":"10.1038/s41392-020-0148-4","keywords":["Immunological disorders","Infectious diseases"],"source":"PubMed","topics":["Diagnosis","Mechanism","Treatment"],"weight":1,"_version_":1663352135307231233,"score":204.34814},{"pmid":32297796,"title":"Description and Proposed Management of the Acute COVID-19 Cardiovascular Syndrome.","text":["Description and Proposed Management of the Acute COVID-19 Cardiovascular Syndrome.","Coronavirus Disease 2019 (COVID-19) is a rapidly expanding global pandemic due to Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) resulting in significant morbidity and mortality. A substantial minority of patients hospitalized develop an Acute COVID-19 Cardiovascular Syndrome (ACovCS) that can manifest with a variety of clinical presentations, but often presents as an acute cardiac injury with cardiomyopathy, ventricular arrhythmias and hemodynamic instability in the absence of obstructive coronary artery disease. The etiology of this injury is uncertain, but is suspected to be related to myocarditis, microvascular injury, systemic cytokine-mediated injury or stress-related cardiomyopathy. Although histologically unproven, SARS-CoV-2 has the potential to directly replicate within cardiomyocytes and pericytes leading to viral myocarditis. Systemically elevated cytokines are also known to be cardiotoxic and have the potential to result in profound myocardial injury. Prior experience with Severe Acute Respiratory Syndrome Coronavirus-1 (SARS-CoV-1) has helped expedite the evaluation of several promising therapies including anti-viral agents, interleukin-6 inhibitors, and convalescent serum. Management of ACovCS should involve a multidisciplinary team including intensive care specialists, infectious disease specialists and cardiologists. Priorities for managing ACovCS include balancing the goals of minimizing healthcare staff exposure for testing that will not change clinical management with early recognition of the syndrome at a time point where intervention may be most effective. The aim of this paper is to review the best available data on ACovCS epidemiology, pathogenesis, diagnosis and treatment. From these data, we propose a surveillance, diagnostic and management strategy that balances potential patient risks and healthcare staff exposure with improvement in meaningful clinical outcomes.","Circulation","Hendren, Nicholas S","Drazner, Mark H","Bozkurt, Biykem","Cooper, Leslie T Jr","32297796"],"abstract":["Coronavirus Disease 2019 (COVID-19) is a rapidly expanding global pandemic due to Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) resulting in significant morbidity and mortality. A substantial minority of patients hospitalized develop an Acute COVID-19 Cardiovascular Syndrome (ACovCS) that can manifest with a variety of clinical presentations, but often presents as an acute cardiac injury with cardiomyopathy, ventricular arrhythmias and hemodynamic instability in the absence of obstructive coronary artery disease. The etiology of this injury is uncertain, but is suspected to be related to myocarditis, microvascular injury, systemic cytokine-mediated injury or stress-related cardiomyopathy. Although histologically unproven, SARS-CoV-2 has the potential to directly replicate within cardiomyocytes and pericytes leading to viral myocarditis. Systemically elevated cytokines are also known to be cardiotoxic and have the potential to result in profound myocardial injury. Prior experience with Severe Acute Respiratory Syndrome Coronavirus-1 (SARS-CoV-1) has helped expedite the evaluation of several promising therapies including anti-viral agents, interleukin-6 inhibitors, and convalescent serum. Management of ACovCS should involve a multidisciplinary team including intensive care specialists, infectious disease specialists and cardiologists. Priorities for managing ACovCS include balancing the goals of minimizing healthcare staff exposure for testing that will not change clinical management with early recognition of the syndrome at a time point where intervention may be most effective. The aim of this paper is to review the best available data on ACovCS epidemiology, pathogenesis, diagnosis and treatment. From these data, we propose a surveillance, diagnostic and management strategy that balances potential patient risks and healthcare staff exposure with improvement in meaningful clinical outcomes."],"journal":"Circulation","authors":["Hendren, Nicholas S","Drazner, Mark H","Bozkurt, Biykem","Cooper, Leslie T Jr"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32297796","week":"202016|Apr 13 - Apr 19","doi":"10.1161/CIRCULATIONAHA.120.047349","keywords":["Coronavirus Disease 2019"],"source":"PubMed","topics":["Prevention","Treatment","Diagnosis","Mechanism"],"weight":1,"locations":["ACovCS","ACovCS"],"_version_":1664266651188592640,"score":78.38164},{"pmid":32109279,"pmcid":"PMC7108195","title":"Clinical Characteristics of Imported Cases of COVID-19 in Jiangsu Province: A Multicenter Descriptive Study.","text":["Clinical Characteristics of Imported Cases of COVID-19 in Jiangsu Province: A Multicenter Descriptive Study.","BACKGROUND: We aimed to report the clinical characteristics of imported coronavirus disease-19 (COVID-19) in Jiangsu Province. METHODS: We retrospectively investigated the clinical, imaging, and laboratory characteristics of confirmed cases of COVID-19 with WHO interim guidance in three Grade A hospitals of Jiangsu from Jan 22 to Feb 14, 2020. Real time RT-PCR was used to detect the new coronavirus in respiratory samples. RESULTS: Of the 80 patients infected with COVID-19, 41 patients were female, with a median age of 46.1 years. Except for 3 severe patients, the rest of the 77 patients exhibited mild or moderate symptoms. 9 patients were unconfirmed until a third-time nucleic acid test. 38 cases had a history of chronic diseases. The main clinical manifestations of the patients were fever and cough, which accounted for 63 cases (78.75%) and 51 cases (-63.75%) respectively. Only 3 patients (3.75%) showed liver dysfunction. Imaging examination showed that 55 patients (-68.75%) showed abnormal, 25 cases (31.25%) had no abnormal density shadow in the parenchyma of both lungs. Up to now, 21 cases were discharged from the hospital, and no patient died. The average length of stay for discharged patients was 8 days. CONCLUSIONS: Compared with the cases in Wuhan, the cases in Jiangsu exhibited mild or moderate symptoms and no obvious gender susceptivity. The proportion of patients having liver dysfunction and abnormal CT imaging was relatively lower than that of Wuhan. Notably, infected patients may be falsely excluded based on two consecutively negative respiratory pathogenic nucleic acid test results.","Clin Infect Dis","Wu, Jian","Liu, Jun","Zhao, Xinguo","Liu, Chengyuan","Wang, Wei","Wang, Dawei","Xu, Wei","Zhang, Chunyu","Yu, Jiong","Jiang, Bin","Cao, Hongcui","Li, Lanjuan","32109279"],"abstract":["BACKGROUND: We aimed to report the clinical characteristics of imported coronavirus disease-19 (COVID-19) in Jiangsu Province. METHODS: We retrospectively investigated the clinical, imaging, and laboratory characteristics of confirmed cases of COVID-19 with WHO interim guidance in three Grade A hospitals of Jiangsu from Jan 22 to Feb 14, 2020. Real time RT-PCR was used to detect the new coronavirus in respiratory samples. RESULTS: Of the 80 patients infected with COVID-19, 41 patients were female, with a median age of 46.1 years. Except for 3 severe patients, the rest of the 77 patients exhibited mild or moderate symptoms. 9 patients were unconfirmed until a third-time nucleic acid test. 38 cases had a history of chronic diseases. The main clinical manifestations of the patients were fever and cough, which accounted for 63 cases (78.75%) and 51 cases (-63.75%) respectively. Only 3 patients (3.75%) showed liver dysfunction. Imaging examination showed that 55 patients (-68.75%) showed abnormal, 25 cases (31.25%) had no abnormal density shadow in the parenchyma of both lungs. Up to now, 21 cases were discharged from the hospital, and no patient died. The average length of stay for discharged patients was 8 days. CONCLUSIONS: Compared with the cases in Wuhan, the cases in Jiangsu exhibited mild or moderate symptoms and no obvious gender susceptivity. The proportion of patients having liver dysfunction and abnormal CT imaging was relatively lower than that of Wuhan. Notably, infected patients may be falsely excluded based on two consecutively negative respiratory pathogenic nucleic acid test results."],"journal":"Clin Infect Dis","authors":["Wu, Jian","Liu, Jun","Zhao, Xinguo","Liu, Chengyuan","Wang, Wei","Wang, Dawei","Xu, Wei","Zhang, Chunyu","Yu, Jiong","Jiang, Bin","Cao, Hongcui","Li, Lanjuan"],"date":"2020-02-29T11:00:00Z","year":2020,"_id":"32109279","week":"20209|Feb 24 - Mar 01","doi":"10.1093/cid/ciaa199","keywords":["Coronavirus disease-19 (COVID-19)","clinical characteristics","imported cases","pneumonia"],"source":"PubMed","locations":["Jiangsu","Wuhan"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis","Mechanism"],"weight":1,"_version_":1663352134396018689,"score":75.28528},{"pmid":32004165,"title":"Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study.","text":["Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study.","BACKGROUND: Human infections with zoonotic coronaviruses (CoVs), including severe acute respiratory syndrome (SARS)-CoV and Middle East respiratory syndrome (MERS)-CoV, have raised great public health concern globally. Here, we report a novel bat-origin CoV causing severe and fatal pneumonia in humans. METHODS: We collected clinical data and bronchoalveolar lavage (BAL) specimens from five patients with severe pneumonia from Jin Yin-tan Hospital of Wuhan, Hubei province, China. Nucleic acids of the BAL were extracted and subjected to next-generation sequencing. Virus isolation was carried out, and maximum-likelihood phylogenetic trees were constructed. RESULTS: Five patients hospitalized from December 18 to December 29, 2019 presented with fever, cough, and dyspnea accompanied by complications of acute respiratory distress syndrome. Chest radiography revealed diffuse opacities and consolidation. One of these patients died. Sequence results revealed the presence of a previously unknown beta-CoV strain in all five patients, with 99.8% to 99.9% nucleotide identities among the isolates. These isolates showed 79.0% nucleotide identity with the sequence of SARS-CoV (GenBank NC_004718) and 51.8% identity with the sequence of MERS-CoV (GenBank NC_019843). The virus is phylogenetically closest to a bat SARS-like CoV (SL-ZC45, GenBank MG772933) with 87.6% to 87.7% nucleotide identity, but is in a separate clade. Moreover, these viruses have a single intact open reading frame gene 8, as a further indicator of bat-origin CoVs. However, the amino acid sequence of the tentative receptor-binding domain resembles that of SARS-CoV, indicating that these viruses might use the same receptor. CONCLUSION: A novel bat-borne CoV was identified that is associated with severe and fatal respiratory disease in humans.","Chin Med J (Engl)","Ren, Li-Li","Wang, Ye-Ming","Wu, Zhi-Qiang","Xiang, Zi-Chun","Guo, Li","Xu, Teng","Jiang, Yong-Zhong","Xiong, Yan","Li, Yong-Jun","Li, Xing-Wang","Li, Hui","Fan, Guo-Hui","Gu, Xiao-Ying","Xiao, Yan","Gao, Hong","Xu, Jiu-Yang","Yang, Fan","Wang, Xin-Ming","Wu, Chao","Chen, Lan","Liu, Yi-Wei","Liu, Bo","Yang, Jian","Wang, Xiao-Rui","Dong, Jie","Li, Li","Huang, Chao-Lin","Zhao, Jian-Ping","Hu, Yi","Cheng, Zhen-Shun","Liu, Lin-Lin","Qian, Zhao-Hui","Qin, Chuan","Jin, Qi","Cao, Bin","Wang, Jian-Wei","32004165"],"abstract":["BACKGROUND: Human infections with zoonotic coronaviruses (CoVs), including severe acute respiratory syndrome (SARS)-CoV and Middle East respiratory syndrome (MERS)-CoV, have raised great public health concern globally. Here, we report a novel bat-origin CoV causing severe and fatal pneumonia in humans. METHODS: We collected clinical data and bronchoalveolar lavage (BAL) specimens from five patients with severe pneumonia from Jin Yin-tan Hospital of Wuhan, Hubei province, China. Nucleic acids of the BAL were extracted and subjected to next-generation sequencing. Virus isolation was carried out, and maximum-likelihood phylogenetic trees were constructed. RESULTS: Five patients hospitalized from December 18 to December 29, 2019 presented with fever, cough, and dyspnea accompanied by complications of acute respiratory distress syndrome. Chest radiography revealed diffuse opacities and consolidation. One of these patients died. Sequence results revealed the presence of a previously unknown beta-CoV strain in all five patients, with 99.8% to 99.9% nucleotide identities among the isolates. These isolates showed 79.0% nucleotide identity with the sequence of SARS-CoV (GenBank NC_004718) and 51.8% identity with the sequence of MERS-CoV (GenBank NC_019843). The virus is phylogenetically closest to a bat SARS-like CoV (SL-ZC45, GenBank MG772933) with 87.6% to 87.7% nucleotide identity, but is in a separate clade. Moreover, these viruses have a single intact open reading frame gene 8, as a further indicator of bat-origin CoVs. However, the amino acid sequence of the tentative receptor-binding domain resembles that of SARS-CoV, indicating that these viruses might use the same receptor. CONCLUSION: A novel bat-borne CoV was identified that is associated with severe and fatal respiratory disease in humans."],"journal":"Chin Med J (Engl)","authors":["Ren, Li-Li","Wang, Ye-Ming","Wu, Zhi-Qiang","Xiang, Zi-Chun","Guo, Li","Xu, Teng","Jiang, Yong-Zhong","Xiong, Yan","Li, Yong-Jun","Li, Xing-Wang","Li, Hui","Fan, Guo-Hui","Gu, Xiao-Ying","Xiao, Yan","Gao, Hong","Xu, Jiu-Yang","Yang, Fan","Wang, Xin-Ming","Wu, Chao","Chen, Lan","Liu, Yi-Wei","Liu, Bo","Yang, Jian","Wang, Xiao-Rui","Dong, Jie","Li, Li","Huang, Chao-Lin","Zhao, Jian-Ping","Hu, Yi","Cheng, Zhen-Shun","Liu, Lin-Lin","Qian, Zhao-Hui","Qin, Chuan","Jin, Qi","Cao, Bin","Wang, Jian-Wei"],"date":"2020-02-01T11:00:00Z","year":2020,"_id":"32004165","week":"20205|Jan 27 - Feb 02","doi":"10.1097/CM9.0000000000000722","source":"PubMed","locations":["China","Wuhan","Hubei"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism"],"weight":1,"_version_":1663352134826983424,"score":74.63568},{"pmid":32169481,"pmcid":"PMC7102553","title":"COVID-19 spike-host cell receptor GRP78 binding site prediction.","text":["COVID-19 spike-host cell receptor GRP78 binding site prediction.","OBJECTIVES: Understanding the novel coronavirus (COVID-19) mode of host cell recognition may help to fight the disease and save lives. The spike protein of coronaviruses is the main driving force for host cell recognition. METHODS: In this study, the COVID-19 spike binding site to the cell-surface receptor (Glucose Regulated Protein 78 (GRP78)) is predicted using combined molecular modeling docking and structural bioinformatics. The COVID-19 spike protein is modeled using its counterpart, the SARS spike. RESULTS: Sequence and structural alignments show that four regions, in addition to its cyclic nature have sequence and physicochemical similarities to the cyclic Pep42. Protein-protein docking was performed to test the four regions of the spike that fit tightly in the GRP78 Substrate Binding Domain beta (SBDbeta). The docking pose revealed the involvement of the SBDbeta of GRP78 and the receptor-binding domain of the coronavirus spike protein in recognition of the host cell receptor. CONCLUSIONS: We reveal that the binding is more favorable between regions III (C391-C525) and IV (C480-C488) of the spike protein model and GRP78. Region IV is the main driving force for GRP78 binding with the predicted binding affinity of -9.8kcal/mol. These nine residues can be used to develop therapeutics specific against COVID-19.","J Infect","Ibrahim, Ibrahim M","Abdelmalek, Doaa H","Elshahat, Mohammed E","Elfiky, Abdo A","32169481"],"abstract":["OBJECTIVES: Understanding the novel coronavirus (COVID-19) mode of host cell recognition may help to fight the disease and save lives. The spike protein of coronaviruses is the main driving force for host cell recognition. METHODS: In this study, the COVID-19 spike binding site to the cell-surface receptor (Glucose Regulated Protein 78 (GRP78)) is predicted using combined molecular modeling docking and structural bioinformatics. The COVID-19 spike protein is modeled using its counterpart, the SARS spike. RESULTS: Sequence and structural alignments show that four regions, in addition to its cyclic nature have sequence and physicochemical similarities to the cyclic Pep42. Protein-protein docking was performed to test the four regions of the spike that fit tightly in the GRP78 Substrate Binding Domain beta (SBDbeta). The docking pose revealed the involvement of the SBDbeta of GRP78 and the receptor-binding domain of the coronavirus spike protein in recognition of the host cell receptor. CONCLUSIONS: We reveal that the binding is more favorable between regions III (C391-C525) and IV (C480-C488) of the spike protein model and GRP78. Region IV is the main driving force for GRP78 binding with the predicted binding affinity of -9.8kcal/mol. These nine residues can be used to develop therapeutics specific against COVID-19."],"journal":"J Infect","authors":["Ibrahim, Ibrahim M","Abdelmalek, Doaa H","Elshahat, Mohammed E","Elfiky, Abdo A"],"date":"2020-03-15T11:00:00Z","year":2020,"_id":"32169481","week":"202011|Mar 09 - Mar 15","doi":"10.1016/j.jinf.2020.02.026","keywords":["BiP","COVID-19 spike","GRP78","Pep42","Protein-protein docking","Structural bioinformatics"],"source":"PubMed","locations":["C391-C525"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1663352133980782592,"score":69.540565}]}